A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
暂无分享,去创建一个
K. Takayama | K. Azuma | Tadaaki Yamada | H. Kimura | Shinsaku Tokuda | T. Harada | Yasuhiro Goto | K. Morimoto | T. Takeda | Y. Chihara | O. Hiranuma | Yoshie Morimoto | M. Iwasaku | N. Tamiya | Ryo Sawada | Isao Hasegawa | K. Ito | S. Shiotsu | Osamu Hiranuma | Yusuke Chihara